RxDoctor Payments Data

Lindsey Monin

Nurse Practitioner · Elizabethtown, KYNPI 1790132371

Payments from drug & device makers

$4,738in general payments, 2019–2025

Across 295 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$982
  • AbbVie$731
  • Amgen$532
  • AstraZeneca$439
  • Pfizer$328
  • Lilly USA, LLC$215
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,724100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,738 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$52,055
Medicare patients
170
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$106,596
MounjaroTirzepatide85$105,879
EliquisApixaban41$49,773
FarxigaDapagliflozin Propanediol32$31,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$31,503
ProliaDenosumab13$22,770
TrulicityDulaglutide12$13,187
Repatha SureclickEvolocumab14$11,883
KerendiaFinerenone12$7,413
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,773
Liothyronine Sodium48$2,734
Albuterol Sulfate HfaAlbuterol Sulfate79$2,564
Levothyroxine Sodium261$2,558
Varenicline Tartrate13$2,502
Atorvastatin Calcium379$2,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$215$119,06597 claims
Novo NordiskOzempic$982$106,59669 claims
PfizerEliquis$328$49,77341 claims
AstraZenecaFarxiga$439$31,51532 claims
GSKTrelegy Ellipta$56$31,50328 claims
AmgenProlia$532$22,77013 claims
BayerKerendia$69$7,41312 claims
AbbVieSynthroid$731$1,22045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →